{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T23:27:57Z","timestamp":1780442877335,"version":"3.54.1"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"1","content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Theor Biol Med Model"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1186\/s12976-017-0073-6","type":"journal-article","created":{"date-parts":[[2018,1,4]],"date-time":"2018-01-04T13:58:34Z","timestamp":1515074314000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["A patient-specific treatment model for Graves\u2019 hyperthyroidism"],"prefix":"10.1186","volume":"15","author":[{"given":"Balamurugan","family":"Pandiyan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen J.","family":"Merrill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Flavia","family":"Di Bari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Antonelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salvatore","family":"Benvenga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,1,9]]},"reference":[{"issue":"23","key":"73_CR1","doi-asserted-by":"crossref","first-page":"2544","DOI":"10.1001\/jama.2015.16535","volume":"314","author":"HB Burch","year":"2015","unstructured":"Burch HB, Cooper DS. Management of Graves Disease: A Review. JAMA. 2015; 314(23):2544\u201354.","journal-title":"JAMA"},{"key":"73_CR2","first-page":"114","volume":"59 Suppl 1","author":"AP Weetman","year":"2003","unstructured":"Weetman AP. Grave\u2019s disease 1835-2002. Horm Res. 2003; 59 Suppl 1:114\u20138.","journal-title":"Horm Res"},{"key":"73_CR3","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1016\/S0140-6736(16)00278-6","volume":"388","author":"S De Leo","year":"2016","unstructured":"De Leo S, Lee SY, Braverman LE. Hyperthyroidism. Lancet. 2016; 388:906\u2013918.","journal-title":"Lancet"},{"issue":"23","key":"73_CR4","first-page":"3611","volume":"18","author":"YH Dong","year":"2014","unstructured":"Dong YH, Fu DG. Autoimmune thyroid disease: mechanism, genetics and current knowledge. Eur Rev Med Pharmacol Sci. 2014; 18(23):3611\u20138.","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"73_CR5","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.jaut.2015.07.009","volume":"64","author":"HJ Lee","year":"2015","unstructured":"Lee HJ, Li CW, Hammerstad SS, Stefan M, Tomer Y. Immunogenetics of autoimmune thyroid diseases: A comprehensive review. J Autoimmun. 2015; 64:82\u201390.","journal-title":"J Autoimmun"},{"issue":"10","key":"73_CR6","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1055\/s-0035-1555901","volume":"47","author":"S Neumann","year":"2015","unstructured":"Neumann S, Place RF, Krieger CC, Gershengorn MC. Future Prospects for the Treatment of Graves\u2019 Hyperthyroidism and Eye Disease. Horm Metab Res. 2015; 47(10):789\u201396.","journal-title":"Horm Metab Res"},{"issue":"5","key":"73_CR7","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1111\/cen.12060","volume":"78","author":"HF Nystrom","year":"2013","unstructured":"Nystrom HF, Jansson S, Berg G. Incidence rate and clinical features of hyperthyroidism in a long-term iodine sufficient area of Sweden (Gothenburg) 2003-2005. Clin Endocrinol (Oxf). 2013; 78(5):768\u201376.","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"24","key":"73_CR8","doi-asserted-by":"crossref","first-page":"2594","DOI":"10.1056\/NEJMcp0801880","volume":"358","author":"GA Brent","year":"2008","unstructured":"Brent GA. Clinical practice. Graves\u2019 disease. N Engl J Med. 2008; 358(24):2594\u2013605.","journal-title":"N Engl J Med"},{"key":"73_CR9","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.jtbi.2014.12.015","volume":"375","author":"SJ Merrill","year":"2015","unstructured":"Merrill SJ, Mu Y. Thyroid autoimmunity as a window to autoimmunity: An explanation for sex differences in the prevalence of thyroid autoimmunity. J Theor Biol. 2015; 375:95\u2013100.","journal-title":"J Theor Biol"},{"issue":"2","key":"73_CR10","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1530\/acta.0.1010193","volume":"101","author":"L Tegler","year":"1982","unstructured":"Tegler L, Gillquist J, Lindvall R, Almqvist S. Secretion rates of thyroxine, triiodothyronine, and reverse triiodothyronine in man during surgery. Acta Endocrinol. 1982; 101(2):193\u20138.","journal-title":"Acta Endocrinol"},{"issue":"10","key":"73_CR11","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1089\/thy.2016.0229","volume":"26","author":"DS Ross","year":"2016","unstructured":"Ross DS, Burch HB, Cooper DS, Greenlee MC, Laurberg P, Maia AL, Rivkees SA, Samuels M, Sosa JA, Stan MN, Walter MA. 2016 American Thyroid Association Guidelines for Diagnosis and Management of Hyperthyroidism and Other Causes of Thyrotoxicosis. Thyroid. 2016; 26(10):1343\u2013421.","journal-title":"Thyroid"},{"issue":"4-5","key":"73_CR12","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1016\/j.autrev.2014.01.013","volume":"13","author":"F Menconi","year":"2014","unstructured":"Menconi F, Marcocci C, Marino M. Diagnosis and classification of Graves\u2019 disease. Autoimmun Rev. 2014; 13(4-5):398\u2013402.","journal-title":"Autoimmun Rev"},{"issue":"1","key":"73_CR13","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1089\/105072503321086962","volume":"13","author":"Z Baloch","year":"2003","unstructured":"Baloch Z, Carayon P, Conte-Devolx B, Demers LM, Feldt-Rasmussen U, Henry JF, LiVosli VA, Niccoli-Sire P, John R, Ruf J, Smyth PP, Spencer CA, Stockigt JR. Laboratory medicine practice guidelines. Laboratory support for the diagnosis and monitoring of thyroid disease. Thyroid. 2003; 13(1):3\u2013126.","journal-title":"Thyroid"},{"issue":"10","key":"73_CR14","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1055\/s-0030-1253420","volume":"118","author":"A Fumarola","year":"2010","unstructured":"Fumarola A, Di Fiore A, Dainelli M, Grani G, Calvanese A. Medical treatment of hyperthyroidism: state of the art. Exp Clin Endocrinol Diabetes. 2010; 118(10):678\u201384.","journal-title":"Exp Clin Endocrinol Diabetes"},{"issue":"3","key":"73_CR15","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1111\/j.1365-2125.1974.tb00248.x","volume":"1","author":"GG Skellern","year":"1974","unstructured":"Skellern GG, Stenlake JB, Williams WD, McLarty DG. Plasma concentrations of methimazole, a metabolite of carbimazole, in hyperthyroid patients. Br J Clin Pharmacol. 1974; 1(3):265\u20139.","journal-title":"Br J Clin Pharmacol"},{"issue":"5","key":"73_CR16","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1507\/endocrj1954.33.605","volume":"33","author":"Y Okamura","year":"1986","unstructured":"Okamura Y, Shigemasa C, Tatsuhara T. Pharmacokinetics of methimazole in normal subjects and hyperthyroid patients. Endocrinol Jpn. 1986; 33(5):605\u201315.","journal-title":"Endocrinol Jpn"},{"issue":"3","key":"73_CR17","doi-asserted-by":"crossref","first-page":"340","DOI":"10.4103\/2230-8210.152766","volume":"19","author":"M John","year":"2015","unstructured":"John M, Sundrarajan R, Gomadam SS. Anti-thyroid drugs in pediatric Graves\u2019 disease. Indian J Endocrinol Metab. 2015; 19(3):340\u20136.","journal-title":"Indian J Endocrinol Metab"},{"issue":"6","key":"73_CR18","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1530\/eje.1.02295","volume":"155","author":"P Laurberg","year":"2006","unstructured":"Laurberg P. Remission of Graves\u2019 disease during anti-thyroid drug therapy. Time to reconsider the mechanism?Eur J Endocrinol. 2006; 155(6):783\u20136.","journal-title":"Eur J Endocrinol"},{"issue":"2","key":"73_CR19","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1001\/archinte.1958.00260140196029","volume":"101","author":"TE Prout","year":"1958","unstructured":"Prout TE, Asper SP. Exacerbation of hyperthyroidism by methimazole during iodide therapy. AMA Arch Intern Med. 1958; 101(2):364\u20138.","journal-title":"AMA Arch Intern Med"},{"issue":"4","key":"73_CR20","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1007\/s11154-016-9386-8","volume":"17","author":"C Langenstein","year":"2016","unstructured":"Langenstein C, Schork D, Badenhoop K, Herrmann E. Relapse prediction in Graves disease: Towards mathematical modeling of clinical, immune and genetic markers. Rev Endocr Metab Disord. 2016; 17(4):571\u201381.","journal-title":"Rev Endocr Metab Disord"},{"issue":"2","key":"73_CR21","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1210\/jcem-33-2-182","volume":"33","author":"J Pittman","year":"1971","unstructured":"Pittman J, Beschi R, Smitherman T. Methimazole: its absorption and excretion in man and tissue distribution in rats. J Clin Endocrinol Metab. 1971; 33(2):182\u20135.","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"73_CR22","doi-asserted-by":"crossref","first-page":"443","DOI":"10.2165\/00003088-198510050-00006","volume":"10","author":"R Jansson","year":"1985","unstructured":"Jansson R, Lindstr\u00f6m B, Dahlberg P. Pharmacokinetic properties and bioavailability of methimazole. Clin Pharmacokinet. 1985; 10(5):443\u201350.","journal-title":"Clin Pharmacokinet"},{"issue":"5","key":"73_CR23","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1124\/mol.60.5.972","volume":"60","author":"H Kim","year":"2001","unstructured":"Kim H, Lee TH, Hwang YS, Bang MA, Kim KH, Suh JM, Chung HK, Yu DY, Lee KK, Kwon OY, et al.Methimazole as an antioxidant and immunomodulator in thyroid cells: mechanisms involving interferon- \u03b3 signaling and h2o2 scavenging. Mol Pharmacol. 2001; 60(5):972\u201380.","journal-title":"Mol Pharmacol"},{"issue":"4","key":"73_CR24","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1007\/BF00613617","volume":"23","author":"K Johansen","year":"1982","unstructured":"Johansen K, Andersen AN, Kampmann J, Hansen JM, Mortensen H. Excretion of methimazole in human milk. Eur J Clin Pharmacol. 1982; 23(4):339\u201341.","journal-title":"Eur J Clin Pharmacol"},{"issue":"8","key":"73_CR25","first-page":"3488","volume":"86","author":"VA Andrade","year":"2001","unstructured":"Andrade VA, Gross JL, Maia AL. The effect of methimazole pretreatment on the efficacy of radioactive iodine therapy in graves hyperthyroidism: one-year follow-up of a prospective, randomized study. J Clin Endocrinol Metab. 2001; 86(8):3488\u201393.","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"73_CR26","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1093\/imammb\/dqt005","volume":"31","author":"B Pandiyan","year":"2014","unstructured":"Pandiyan B, Merrill SJ, Benvenga S. A patient-specific model of the negative-feedback control of the hypothalamus-pituitary-thyroid (HPT) axis in autoimmune (Hashimoto\u2019s) thyroiditis. Math Med Biol. 2014; 31(3):226\u201358.","journal-title":"Math Med Biol"},{"issue":"1","key":"73_CR27","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1210\/jcem-57-1-129","volume":"57","author":"R Jansson","year":"1983","unstructured":"Jansson R, Dahlberg PA, Johansson H, Lindstr\u00d6m B. Intrathyroidal concentrations of methimazole in patients with graves disease. J Clin Endocrinol Metab. 1983; 57(1):129\u201332.","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"73_CR28","first-page":"301","volume":"71","author":"G Huang","year":"1991","unstructured":"Huang G. [Relation between the dosage of methimazole and its intrathyroidal concentrations]. Zhonghua Yi Xue Za Zhi. 1991; 71(6):301\u20133.","journal-title":"Zhonghua Yi Xue Za Zhi"},{"key":"73_CR29","doi-asserted-by":"crossref","DOI":"10.1137\/1.9780898719147","volume-title":"Mathematical Models in Biology.","author":"L Edelstein-Keshet","year":"2005","unstructured":"Edelstein-Keshet L. Mathematical Models in Biology.Philadelphia: Society for Industrial and Applied Mathematics (SIAM); 2005."},{"key":"73_CR30","unstructured":"Online Conversion Calculator. http:\/\/unitslab.com\/node\/121. Accessed 19 May 2017."},{"key":"73_CR31","doi-asserted-by":"publisher","unstructured":"Pandiyan B, Merrill SJ, Benvenga S. A homoclinic orbit in a patient-specific model of hashimotos thyroiditis. Diff Equ Dyn Syst. 2016;:1\u201318. https:\/\/doi.org\/10.1007\/s12591-016-0335-5.","DOI":"10.1007\/s12591-016-0335-5"}],"container-title":["Theoretical Biology and Medical Modelling"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12976-017-0073-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,10,9]],"date-time":"2019-10-09T01:11:01Z","timestamp":1570583461000},"score":1,"resource":{"primary":{"URL":"https:\/\/tbiomed.biomedcentral.com\/articles\/10.1186\/s12976-017-0073-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,1,9]]},"references-count":31,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["73"],"URL":"https:\/\/doi.org\/10.1186\/s12976-017-0073-6","relation":{},"ISSN":["1742-4682"],"issn-type":[{"value":"1742-4682","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,1,9]]},"article-number":"1"}}